Information de reference pour ce titreAccession Number: | 00063198-200301000-00008.
|
Author: | Braunstahl, Gert-Jan MD, PhD; Hellings, Peter W. MD, PhD
|
Institution: | *Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; (+)Department of Otorhinolaryngology, University Hospitals, Leuven, Belgium.
|
Title: | |
Source: | Current Opinion in Pulmonary Medicine. 9(1):46-51, January 2003.
|
Abstract: | Allergic asthma and rhinitis are manifestations of the atopic syndrome. Although the diseases commonly occur together, it is still unclear why some allergic patients develop only asthma and others only rhinitis. The reason for the variety in clinical expression of allergic airway disease is not known. Besides a genetic predisposition, environmental factors contribute to the development of the allergic phenotype. Local and systemic inflammatory processes also seem to be involved, however, their exact contribution to the clinical picture of airway allergy still remains to be elucidated. Although it is clear that the condition of the upper airways has an impact on lower airway physiology, the mechanisms underlying this relation are far from being resolved. To date, most data point towards a systemic link between upper and lower airways, involving bloodstream and bone marrow. In this article, the latest developments with regard to nasobronchial interaction in allergic airway disease will be reviewed. Epidemiologic, experimental and clinical data underline the importance of a global approach in allergic rhinitis and asthma.
Copyright (C) 2003 Wolters Kluwer Health, Inc. All rights reserved.
|
References: | 1.** Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S147-334. State-of-the-art work based on a extensive review of over 2700 papers. This review provides an evidence-based guideline for diagnosis and therapy in allergic rhinitis. Moreover, it emphasizes the importance of a global approach in allergic rhinitis and asthma.
2. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998, 351:1225-1232.
3. Upton MN, McConnachie A, McSharry C, et al.: Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000, 321:88-92.
4. Guerra S, Sherrill DL, Martinez FD, et al.: Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002, 109:419-425.
5. Aberg N: Familial occurrence of atopic disease: genetic versus environmental factors. Clin Exp Allergy 1993, 23:829-834.
6. Aberg N, Sundell J, Eriksson B, et al.: Prevalence of allergic diseases in schoolchildren in relation to family history, upper respiratory infections, and residential characteristics. Allergy 1996, 51:232-237.
7. Janson C, Anto J, Burney P, et al.: The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J 2001, 18:598-611.
8. Leynaert B, Neukirch C, Jarvis D, et al.: Does living on a farm during childhood protect against asthma, allergic rhinitis, and atopy in adulthood? Am J Respir Crit Care Med 2001, 164:1829-1834.
9. Riedler J, Braun-Fahrlander C, Eder W, et al.: Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001, 358:1129-1133.
10. Custovic A, Simpson BM, Simpson A, et al.: Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomized trial. Lancet 2001, 358:188-193.
11. Janson C, Chinn S, Jarvis D, et al.: Effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health Survey: a cross-sectional study. Lancet 2001, 358:2103-2109.
12. McLane ML, Nelson JA, Lenner KA, et al.: Integrated response of the upper and lower respiratory tract of asthmatic subjects to frigid air. J Appl Physiol 2000, 88:1043-1050.
13.* Assanasen P, Baroody FM, Naureckas E, et al.: The nasal passage of subjects with asthma has a decreased ability to warm and humidify inspired air. Am J Respir Crit Care Med 2001, 164:1640-1646. This elegant study compares several phenotypes of the allergic spectrum in their ability to condition air.
14. Hellgren J, Toren K, Balder B, et al.: Increased nasal mucosal swelling in subjects with asthma. Clin Exp Allergy 2002, 32:64-69.
15. van den Toorn LM, Overbeek SE, de Jongste JC, et al.: Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 2001, 164:2107-2113.
16. De Meer G, Heederik D, Postma DS: Bronchial responsiveness to adenosine 5[spacing acute]-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV(1). Am J Respir Crit Care Med 2002, 165:327-331.
17. Lamblin C, Gosset P, Salez F, et al.: Eosinophilic airway inflammation in nasal polyposis. J Allergy Clin Immunol 1999, 104:85-92.
18.* ten Brinke A, Grootendorst DC, Schmidt JT, et al.: Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002, 109:621-626. This study in patients with severe bronchial asthma describes the influence of sinus disease on the lower airways by using several parameters: CT scans of the sinuses, various lung function tests, sputum eosinophilia and exhaled NO concentration.
19. Corren J, Adinoff AD, Irvin CG: Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992, 89:611-618.
20. Bardin PG, Van Heerden BB, Joubert JR: Absence of pulmonary aspiration of sinus contents in patients with asthma and sinusitis. J Allergy Clin Immunol 1990, 86:82-88.
21. Nolte D, Berger D: On vagal bronchoconstriction in asthmatic patients by nasal irritation. Eur J Respir Dis Suppl 1983, 128:110-115.
22. Rosenberg GL, Rosenthal RR, Norman PS: Inhalation challenge with ragweed pollen in ragweed-sensitive asthmatics. J Allergy Clin Immunol 1983, 71:302-310.
23. Schumacher MJ, Cota KA, Taussig LM: Pulmonary response to nasal-challenge testing of atopic subjects with stable asthma. J Allergy Clin Immunol 1986, 78:30-35.
24. Littell NT, Carlisle CC, Millman RP, et al: Changes in airway resistance following nasal provocation. Am Rev Respir Dis 1990, 141:580-583.
25. Bousquet J, Vignola AM, Campbell AM, et al.: Pathophysiology of allergic rhinitis. Int Arch Allergy Immunol 1996, 110:207-218.
26. Busse WW, Calhoun WF, Sedgwick JD: Mechanism of airway inflammation in asthma. Am Rev Respir Dis 1993, 147:S20-24
27. Djukanovic R, Roche WR, Wilson JW, et al.: Mucosal inflammation in asthma. Am Rev Respir Dis 1990, 142:434-457.
28. Foresi A, Leone C, Pelucchi A, et al.: Eosinophils, mast cells, and basophils in induced sputum from patients with seasonal allergic rhinitis and perennial asthma: relationship to methacholine responsiveness. J Allergy Clin Immunol 1997, 100:58-64.
29. Alvarez MJ, Olaguibel JM, Garcia BE, et al.: Airway inflammation in asthma and perennial allergic rhinitis. relationship with nonspecific bronchial responsiveness and maximal airway narrowing. Allergy 2000, 55:355-362.
30. Sedgwick JB, Calhoun WJ, Gleich GJ, et al.: Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis 1991, 144:1274-1281.
31. Djukanovic R, Lai CK, Wilson JW, et al.: Bronchial mucosal manifestations of atopy: a comparison of markers of inflammation between atopic asthmatics, atopic nonasthmatics and healthy controls. Eur Respir J 1992, 5:538-544.
32. Gaga M, Lambrou P, Papageorgiou N, et al.: Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 2000, 30:663-669.
33. Marcucci F, Sensi LG, Migali E, et al.: Eosinophil cationic protein and specific IgE in serum and nasal mucosa of patients with grass-pollen-allergic rhinitis and asthma. Allergy 2001, 56:231-236.
34. Palczynski C, Walusiak J, Ruta U, et al.: Occupational asthma and rhinitis due to glutaraldehyde: changes in nasal lavage fluid after specific inhalatory challenge test. Allergy 2001, 56:1186-1191.
35. Braunstahl GJ, Kleinjan A, Overbeek SE, et al.: Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000, 161:2051-2057.
36. Braunstahl GJ, Overbeek SE, Kleinjan A, et al.: Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001, 107:469-476.
37.** Brightling CE, Bradding P, Symon FA, et al.: Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699-1705. Interesting article with a clearly defined hypothesis. The relationship between the presence of mast cells in smooth muscle tissue and increased bronchial hyperresponsiveness in patients with asthma sheds new light on the pathophysiology of asthma.
38.* Braunstahl GJ, Overbeek SE, Fokkens WJ, et al.: Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001, 164:858-865. An innovative aspect of the relationship between bronchi and nose was investigated using an experimental approach.
39.* Hellings PW, Hessel EM, Van Den Oord JJ, et al.: Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy 2001, 31:782-790. First report on mouse model of global airway allergy, illustrating the simultaneous induction of eosinophilic inflammation in upper and lower airways and highlighting the systemic character of the inflammatory response following allergen inhalation in mice.
40. Chanez P, Vignola AM, Vic P, et al.: Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med 1999, 159:588-595.
41. Hellings PW, Vandenberghe P, Kasran A, et al.: Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur J Immunol 2002, 32:585-594.
42. Wang J, Palmer K, Lotvall J, et al.: Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998, 102:1132-1141.
43. Tomaki M, Zhao LL, Lundahl J, et al.: Eosinophilopoiesis in a murine model of allergic airway eosinophilia: involvement of bone marrow IL-5 and IL-5 receptor alpha. J Immunol 2000, 165:4040-4050.
44.* Saito H, Matsumoto K, Denburg AE, et al. Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. J Immunol 2002, 168:3017-3023. Innovative study on the role of the IL-5-eosinophil pathway in experimental rhinitis, depicting the important, but not crucial role of IL-5 and eosinophils in nasal symptoms and histamine hyperresponsiveness.
45. Saito H, Howie K, Wattie J, et al.: Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology 2001, 104:226-234.
46.* Crystal-Peters J, Neslusan C, Crown WH, et al.: Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002, 109:57-62. Retrospective cohort study based on insurance claims data. This study clearly demonstrates an inverse relation between allergic rhinitis treatment and asthma related events.
47. Welsh PW, Stricker WE, Chu CP, et al.: Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987, 62:125-134.
48. Foresi A, Pelucchi A, Gherson G, et al.: Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996, 98:274-282.
49. Corren J, Adinoff AD, Buchmeier AD, et al.: Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992, 90:250-256.
50. Lipworth BJ, White PS: Allergic inflammation in the unified airway: start with the nose. Thorax 2000, 55:878-881.
51. Aubier M, Levy J, Clerici C, et al.: Different effects of nasal and bronchial glucocorticosteroid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1992, 146:122-126.
52. Greiff L, Andersson M, Svensson C, et al.: Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J 1998, 11:1268-1273.
53. Woodcock A, Custovic A: ABC of allergies. Avoiding exposure to indoor allergens. BMJ 1998, 316:1075-1078.
54. Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
55.** Bousquet J, Demoly P, Michel FB: Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol 2001, 87:38-42. Evidence-based review of literature published on allergen-specific immunotherapy (SIT) with special emphasis on the effect on asthma. The authors give clear recommendations for the use of SIT in allergic rhinitis and asthma.
56. Moller C, Dreborg S, Ferdousi HA, et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256. Elegant 3-year follow-up study in children with seasonal allergic rhinitis, which investigates the preventive effect of allergen-SIT on the development of asthma.
57.* Rak S, Heinrich C, Jacobsen L, et al.: A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001, 108:921-928. A unique comparative study between allergen-SIT and nasal steroids (NS) in seasonal allergic rhinitis and asthma.
58. Rakoski J, Wessner D: A short assessment of sublingual immunotherapy. Int Arch Allergy Immunol 2001, 126:185-187.
59. Bousquet J, Godard P, Michel FB: Antihistamines in the treatment of asthma. Eur Respir J 1992, 5:1137-1142
60. Baena-Cagnani CE: Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001, 56 Suppl 65:21-27.
61. Henz BM: The pharmacologic profile of desloratadine: a review. Allergy 2001, 56 Suppl 65:7-13.
62. Ciprandi G, Tosca M, Passalacqua G, et al.: Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 2001, 87:222-226.
63. Horwitz RJ, McGill KA, Busse WW: The Role of Leukotriene Modifiers in the Treatment of Asthma. Am J Respir Crit Care Med 1997, 157:1363-1371.
64. Sampson A, Holgate S: Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity. BMJ 1998, 316:1257-1258.
65.* Borish L: The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann Allergy Asthma Immunol 2002, 88:16-22. An excellent review on the pathophysiologic role of leukotrienes in allergic rhinitis and asthma and the therapeutical implications.
66. Schmidt BM, Kusma M, Feuring M, et al.: The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001, 108:530-536.
67. Yoshida N, Shimizu Y, Kitaichi K, et al.: Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells. Clin Exp Immunol 2001, 126:384-389.
68.* Arshad SH, Holgate S: The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody. Clin Exp Allergy 2001, 31:1344-1351. This review gives insight into the immunopathologic functions of immunoglobulin E in allergy and asthma. It provides the rationale for targeting IgE as one of the key players in allergic airway disease.
69. Platts-Mills TA: The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001, 164:S1-5.
70.* Busse W, Corren J, Lanier BQ, et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190. Randomized, double-blinded, placebo-controlled trial involving patients with severe allergic asthma, who are corticoid dependent. This study clearly showed the efficacy and safety of omalizumab in this population.
71.** Holgate S, Bousquet J, Wenzel S, et al.: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001, 17:233-240. Meta-analysis based on three randomized trials investigating the efficacy and public health impact of omalizumab as an add-on therapy in severe allergic asthma.
|
Language: | English.
|
Document Type: | Asthma.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1070-5287
|
NLM Journal Code: | cn1, 9503765
|
Annotation(s) | |
|
|